{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:07:02Z","timestamp":1792620422290,"version":"4.5.0"},"reference-count":33,"publisher":"American Society of Hematology","issue":"14","license":[{"start":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T00:00:00Z","timestamp":1717545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,7,23]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Cytomegalovirus (CMV) reactivation is a major complication among seropositive allogeneic hematopoietic cell transplantation recipients; however, data on CMV reactivation after chimeric antigen receptor (CAR) T-cell therapy are limited. We report the incidence and outcomes of 95 adult CMV-seropositive patients who received CAR T-cell therapy between February 2018 and February 2023. CMV outcomes were CMV reactivation (any viremia) and clinically significant CMV infection (cs-CMV). Thirty-one patients (33%) had evidence of CMV reactivation (any viremia), and 10 patients (11%) had cs-CMV. The median time from CAR T-cell infusion to CMV reactivation was 19\u00a0days (interquartile range [IQR], 9-31). The cumulative incidence of CMV (any viremia) was significantly higher among patients with grade 3 to 4 cytokine release syndrome (67 vs 28%; P\u00a0=\u00a0.01), and those who received corticosteroids (39 vs 21%; P\u00a0=\u00a0.03), anakinra (56 vs 28%; P\u00a0=\u00a0.02), or \u22652 immunosuppressants (41 vs 21%; P\u00a0=\u00a0.02). Receipt of corticosteroids (18 vs 0%; P\u00a0=\u00a0.004), tocilizumab (14 vs 0%; P\u00a0=\u00a0.04), anakinra (33 vs 7%; P\u00a0=\u00a0.008), and \u22652 immunosuppressants (20 vs 0%; P\u00a0=\u00a0.001) were all associated with cs-CMV. Receiving \u22652 immunosuppressants was associated with a twofold increase in CMV reactivation in multivariate analyses (adjusted odds ratio [aOR], 2.27; 95% confidence interval, 1.1-4.8; P\u00a0=\u00a0.03). Overall, the 1-year mortality was significantly higher in those with CMV reactivation (57% vs 23%; P\u00a0=\u00a0.001). Immunosuppression, particularly with corticosteroids, for the management of CAR T-cell toxicities, is a major risk factor for CMV reactivation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024012922","type":"journal-article","created":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T14:56:40Z","timestamp":1717599400000},"page":"3813-3822","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":47,"title":["Incidence and outcomes of cytomegalovirus reactivation after chimeric antigen receptor T-cell therapy"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6226-0375","authenticated-orcid":false,"given":"Rick Y.","family":"Lin","sequence":"first","affiliation":[{"name":"1Department of Medicine, University of Florida, Gainesville, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2765-582X","authenticated-orcid":false,"given":"Anthony D.","family":"Anderson","sequence":"additional","affiliation":[{"name":"2Department of Pharmacy, Sylvester Comprehensive Cancer Center, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4938-125X","authenticated-orcid":false,"given":"Yoichiro","family":"Natori","sequence":"additional","affiliation":[{"name":"3Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4324-5748","authenticated-orcid":false,"given":"Mohammed","family":"Raja","sequence":"additional","affiliation":[{"name":"3Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4479-8726","authenticated-orcid":false,"given":"Michele I.","family":"Morris","sequence":"additional","affiliation":[{"name":"3Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2817-6836","authenticated-orcid":false,"given":"Antonio Jimenez","family":"Jimenez","sequence":"additional","affiliation":[{"name":"4Division of Transplantation and Cellular Therapy, Sylvester Comprehensive Cancer Center, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Beitinjaneh","sequence":"additional","affiliation":[{"name":"4Division of Transplantation and Cellular Therapy, Sylvester Comprehensive Cancer Center, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5685-7204","authenticated-orcid":false,"given":"Trent","family":"Wang","sequence":"additional","affiliation":[{"name":"4Division of Transplantation and Cellular Therapy, Sylvester Comprehensive Cancer Center, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Goodman","sequence":"additional","affiliation":[{"name":"4Division of Transplantation and Cellular Therapy, Sylvester Comprehensive Cancer Center, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lazaros","family":"Lekakis","sequence":"additional","affiliation":[{"name":"4Division of Transplantation and Cellular Therapy, Sylvester Comprehensive Cancer Center, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6491-0044","authenticated-orcid":false,"given":"Jay","family":"Spiegel","sequence":"additional","affiliation":[{"name":"4Division of Transplantation and Cellular Therapy, Sylvester Comprehensive Cancer Center, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noa G.","family":"Holtzman","sequence":"additional","affiliation":[{"name":"4Division of Transplantation and Cellular Therapy, Sylvester Comprehensive Cancer Center, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Pereira","sequence":"additional","affiliation":[{"name":"4Division of Transplantation and Cellular Therapy, Sylvester Comprehensive Cancer Center, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara","family":"Benjamin","sequence":"additional","affiliation":[{"name":"4Division of Transplantation and Cellular Therapy, Sylvester Comprehensive Cancer Center, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akina","family":"Natori","sequence":"additional","affiliation":[{"name":"5Division of Medical Oncology, Sylvester Comprehensive Cancer Center, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna V.","family":"Komanduri","sequence":"additional","affiliation":[{"name":"6Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9584-5011","authenticated-orcid":false,"given":"Jose F.","family":"Camargo","sequence":"additional","affiliation":[{"name":"3Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"issue":"10254","key":"2024072313012766500_bib1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"14","key":"2024072313012766500_bib2","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"2024072313012766500_bib3","doi-asserted-by":"crossref","first-page":"119","DOI":"10.2147\/BLCTT.S327016","article-title":"CAR T-cell therapy for patients with multiple myeloma: current evidence and challenges","volume":"12","author":"Rendo","year":"2022","journal-title":"Blood Lymphat Cancer"},{"issue":"1","key":"2024072313012766500_bib4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2024072313012766500_bib5","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2021","journal-title":"Haematologica"},{"issue":"4","key":"2024072313012766500_bib6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"8","key":"2024072313012766500_bib7","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"issue":"1","key":"2024072313012766500_bib8","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/ejh.13712","article-title":"Characteristics and recognition of early infections in patients treated with commercial anti-CD19 CAR-T cells","volume":"108","author":"Beyar-Katz","year":"2022","journal-title":"Eur J Haematol"},{"issue":"12","key":"2024072313012766500_bib9","doi-asserted-by":"crossref","first-page":"851.e1","DOI":"10.1016\/j.jtct.2022.09.007","article-title":"Impact of cytomegalovirus replication in patients with aggressive B cell lymphoma treated with chimeric antigen receptor T cell therapy","volume":"28","author":"Marquez-Algaba","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"2024072313012766500_bib10","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3324\/haematol.2022.281719","article-title":"Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant","volume":"108","author":"Chen","year":"2023","journal-title":"Haematologica"},{"issue":"4","key":"2024072313012766500_bib11","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/cid\/ciad708","article-title":"CMV reactivation and CMV-specific cell-mediated immunity after chimeric antigen receptor T-cell therapy","volume":"78","author":"Kampouri","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2024072313012766500_bib12","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol"},{"issue":"8","key":"2024072313012766500_bib13","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1182\/blood-2018-10-878918","article-title":"Deep functional immunophenotyping predicts risk of cytomegalovirus reactivation after hematopoietic cell transplantation","volume":"133","author":"Camargo","year":"2019","journal-title":"Blood"},{"issue":"4","key":"2024072313012766500_bib14","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1016\/j.bbmt.2017.11.038","article-title":"Impact of cytomegalovirus viral load on probability of spontaneous clearance and response to preemptive therapy in allogeneic stem cell transplantation recipients","volume":"24","author":"Camargo","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2024072313012766500_bib15","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.3390\/cancers13071684","article-title":"Infection complications after lymphodepletion and dosing of chimeric antigen receptor T (CAR-T) cell therapy in patients with relapsed\/refractory acute lymphoblastic leukemia or B cell non-Hodgkin lymphoma","volume":"13","author":"Korell","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2024072313012766500_bib16","first-page":"20499361211036773","article-title":"Infectious complications of CAR T-cell therapy: a clinical update","volume":"8","author":"Stewart","year":"2021","journal-title":"Ther Adv Infect Dis"},{"issue":"10","key":"2024072313012766500_bib17","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","article-title":"Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy","volume":"57","author":"Wudhikarn","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"2024072313012766500_bib18","doi-asserted-by":"crossref","first-page":"ciae030","DOI":"10.1093\/cid\/ciae030","article-title":"Understanding the clinical significance of cytomegalovirus viremia after chimeric antigen receptor T-cell therapy: should we be treating a value?","author":"Kampouri","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2024072313012766500_bib19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"8","key":"2024072313012766500_bib20","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.cmi.2023.05.010","article-title":"Cytomegalovirus DNAemia in haematological patients undergoing CD19-directed chimeric antigen receptor T-cell therapy: should it be systematically monitored?","volume":"29","author":"Solano de la Asuncion","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"10","key":"2024072313012766500_bib21","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41408-021-00563-8","article-title":"Viral infection\/reactivation during long-term follow-up in multiple myeloma patients with anti-BCMA CAR therapy","volume":"11","author":"Wang","year":"2021","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"2024072313012766500_bib22","doi-asserted-by":"crossref","first-page":"7533","DOI":"10.1182\/blood-2022-167908","article-title":"Cytomegalovirus (CMV) reactivation within in the first year after chimeric antigen receptor (CAR) T cell therapy: experience from the first two years at a major cancer center","volume":"140","author":"Khawaja","year":"2022","journal-title":"Blood"},{"issue":"18","key":"2024072313012766500_bib23","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.3390\/cancers15184671","article-title":"Outcomes of chimeric antigen receptor (CAR) T-cell therapy in patients with large B-cell lymphoma (LBCL): a single-institution experience","volume":"15","author":"Trando","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"9","key":"2024072313012766500_bib24","first-page":"351","article-title":"CMV and HSV pneumonia after immunosuppressive agents for treatment of cytokine release syndrome due to chimeric antigen receptor-modified T (CAR-T)-cell immunotherapy","volume":"44","author":"Heldman","year":"2021","journal-title":"J\u00a0Immunother"},{"key":"2024072313012766500_bib25","doi-asserted-by":"crossref","first-page":"1226148","DOI":"10.3389\/fimmu.2023.1226148","article-title":"Case report: fatal cytomegalovirus pneumonia after CAR-T cell therapy in the long-term follow-up","volume":"14","author":"Cheng","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"2024072313012766500_bib26","first-page":"e23002","article-title":"Post-CD19 chimeric antigen receptor T-cell therapy cytomegalovirus retinitis","volume":"14","author":"Bin Dokhi","year":"2022","journal-title":"Cureus"},{"issue":"2","key":"2024072313012766500_bib27","doi-asserted-by":"crossref","first-page":"490","DOI":"10.3390\/curroncol29020044","article-title":"Cytomegalovirus retinitis and retinal detachment following chimeric antigen receptor T cell therapy for relapsed\/refractory multiple myeloma","volume":"29","author":"Zu","year":"2022","journal-title":"Curr Oncol"},{"key":"2024072313012766500_bib28","doi-asserted-by":"crossref","first-page":"ciae053","DOI":"10.1093\/cid\/ciae053","article-title":"How much does cytomegalovirus viremia matter after chimeric antigen receptor T-cell therapy?","author":"Hammond","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"13","key":"2024072313012766500_bib29","doi-asserted-by":"crossref","first-page":"4358","DOI":"10.1182\/blood-2002-05-1496","article-title":"Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors","volume":"100","author":"Marr","year":"2002","journal-title":"Blood"},{"issue":"3","key":"2024072313012766500_bib30","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/338624","article-title":"High risk of death due to bacterial and fungal infection among cytomegalovirus (CMV)-seronegative recipients of stem cell transplants from seropositive donors: evidence for indirect effects of primary CMV infection","volume":"185","author":"Nichols","year":"2002","journal-title":"J\u00a0Infect Dis"},{"issue":"1","key":"2024072313012766500_bib31","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma","volume":"5","author":"Baird","year":"2021","journal-title":"Blood Adv"},{"issue":"7","key":"2024072313012766500_bib32","doi-asserted-by":"crossref","first-page":"e13866","DOI":"10.1111\/ctr.13866","article-title":"Clinical \"real-world\" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients","volume":"34","author":"Anderson","year":"2020","journal-title":"Clin Transplant"},{"issue":"25","key":"2024072313012766500_bib33","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N\u00a0Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/14\/3813\/2235750\/blooda_adv-2024-012922-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/14\/3813\/2235750\/blooda_adv-2024-012922-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T09:26:36Z","timestamp":1721726796000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/14\/3813\/516362\/Incidence-and-outcomes-of-cytomegalovirus"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":33,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2024,7,23]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024012922","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,12]]}}}